Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMYHN59)

Drug Name
Axicabtagene ciloleucel Drug Info
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Approved [1]
Large B-cell lymphoma 2A81 Approved [2]
Follicular lymphoma 2A80 Phase 2/3 [3]
Mantle cell lymphoma 2A85.5 Phase 2/3 [4]
Primary mediastinal B-cell lymphoma 2A81 Phase 2/3 [3]
Non-hodgkin lymphoma 2B33.5 Phase 2 [3]
Acute lymphoblastic leukaemia 2A85 Phase 1 [4]
Cross-matching ID
TTD Drug ID
DMYHN59

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
B-lymphocyte surface antigen B4 (CD19) DTT CD19 5.758 6.211 6.083 5.396
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diffuse large B-cell lymphoma
ICD Disease Classification 2A81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)